Pomerantz Investigates Investor Claims Against Altimmune, Inc.
Investigation of Altimmune, Inc.
Pomerantz LLP is conducting an investigation concerning claims made by investors of Altimmune, Inc. (ALT). This inquiry seeks to determine if the company and its officers engaged in fraudulent activities or violated securities regulations.
Background Information
The investigation follows recent announcements by Altimmune regarding the results from its IMPACT Phase 2b trial of pemvidutide. These trials focused on metabolic dysfunction-associated steatohepatitis (MASH). While the company reported "positive" outcomes from the trial, the statistical significance of the reported effects has raised concerns among investors.
Trial Results Explained
On June 26, 2025, Altimmune shared the trial's topline results. The company indicated an improvement in fibrosis without causing worsening of MASH. However, the differences in outcomes between the treatment group and placebo appeared not to be statistically significant. Specifically, the results showed improvements of 31.8% and 34.5% for two dosages of pemvidutide, while the placebo group achieved an improvement of only 25.9%.
Impact on Stock Price
Following the announcement of these trial results, the market reacted negatively. Altimmune's stock dropped significantly, closing down $4.10 per share, representing a fall of 53.18%, with the closing price reaching $3.61 per share on the same day.
About Pomerantz LLP
Pomerantz LLP is recognized as a leading firm specializing in corporate, securities, and antitrust class actions. Established over 85 years ago by Abraham L. Pomerantz, the firm has a history of advocating for investors' rights while recovering substantial damages on their behalf. With offices in several global cities including New York and Tel Aviv, Pomerantz remains committed to holding corporations accountable for misconduct.
Next Steps for Investors
Investors affected by Altimmune's recent actions are encouraged to reach out to Pomerantz LLP for consultation. Danielle Peyton is available for inquiries at 646-581-9980, ext. 7980, or through email.
How to Connect
If you believe you have been impacted by potential securities fraud related to Altimmune, consider contacting Pomerantz for guidance on the next steps regarding your investments.
Frequently Asked Questions
What is the main focus of the Pomerantz investigation?
The investigation focuses on whether Altimmune and certain officers engaged in securities fraud or other unlawful practices.
What significant event prompted the investigation?
The investigation was prompted by the release of trial results from Altimmune’s study, which caused a significant drop in stock price.
Who can investors contact for more information?
Investors can contact Danielle Peyton at Pomerantz LLP for more details regarding the investigation.
What was the result of the recent trial conducted by Altimmune?
While Altimmune reported positive results, the improvements noted in the trial were not statistically significant, leading to market concerns.
How has the stock price for Altimmune changed recently?
Following the announced trial results, Altimmune's stock price fell dramatically, decreasing by over 53%.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.